Charting, page-202

Interesting L&D. I’ve come across Graft vs Host Disease, and note MSB has a biological agent to combat it. I understand your analogy with FDA approval, as a cautionary tale to prepare for delays.

At this stage we have not heard anything questionable about EBR’s trial results. And taking your analogy further, there is no evidence to date of anything resembling a physiological rejection of EBR’s device, unlike rejection of say tissue/blood from one patient that’s been introduced to another patient. Indeed we’ve been told the device is well tolerated, as we’d expect, noting competitors pacemakers are much larger and more likely to present problems, potentially.

Good to know MSB finally got rewarded in the end. Here’s hoping EBR does likewise!